Utolsó frissítés :
19/11/2024
Antibiotikum   Oxacillin sodium  
Injekció
Az oldatok stabilitása A keverékek stabilitása Stabilitást befolyásoló tényezők Kompatibilitás Az alkalmazás módja Irodalom pdf
   Kémiai szerkezet   

Kereskedelmi név   Kereskedelmi név     

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Bactocill Amerikai Egyesült Államok
Bioxalin Peru
Bristopen Marokkó
Istopen Franciaország
Lioxac Peru
Oxacil Tunézia
Oxacilil Brazília
Oxacilina Brazília, Colombia, Ecuador, Peru, Románia, Venezuela
Oxacillin Amerikai Egyesült Államok
Oxacip Venezuela
Oxalin Peru
Oxamicin Venezuela
Oxanon Brazília
Oxipen Venezuela
Pebenal Venezuela
Staphymicine Marokkó
Irodalom   Injekció   Irodalom : Oxacillin sodium  
Type publikáció
13 Napló Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
73 Napló Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
150 Napló Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
198 Napló Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
336 Napló Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Napló Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
371 Napló Thompson DF, Stiles ML, Allen LV, Tu YH.
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 142-145.
386 Napló Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
397 Napló Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
405 Napló Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
479 Napló Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
496 Napló Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
576 Napló Holmes CJ, Ausman RK, Walter CW, Kundsin RB.
Activity of antibiotic admixtures subjected to different freeze-thaw treatments.
Drug Intell Clin Pharm 1980 ; 14: 353-357.
604 Laboratórium Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
738 Napló Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584.
999 Napló Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1047 Napló Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Napló Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Napló Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135 Napló Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 Napló Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1705 Napló Zhang Y, Trissel LA.
Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags.
Int J Pharm Compound 2002 ; 6: 226-229.
1802 Napló Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
3227 Napló Simon B, Hancu G, Gy?resi A.
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520 Laboratórium Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3529 Laboratórium Ciprofloxacin – Summary of Product Characteristics
Hospira 2013
3549 Laboratórium Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Laboratórium Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3589 Laboratórium Oxacilline PanPharma – Résumé des caractéristiques du produits
PanPharma 2013
3638 Laboratórium Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010
3643 Laboratórium Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 Laboratórium Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3813 Napló Teibel H.M, Knoderer C.A, Nichols K.R.
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
Hosp Pharm 2015 ; 50, 8: 710-713.

  Mentions Légales